All you need to know about survivorship in lymphoma in adults and AYA patients

Abstract

Purpose of review: While advances in lymphoma treatment have improved survival, they are accompanied by a variety of late effects that affect physical health, psychosocial well being, and social reintegration. This review highlights data from recent publications on lymphoma patient survival, including in adolescent and young adult (AYA) patients. Its goal is to support the development of personalized, evidence-based strategies to meet the complex needs of lymphoma survivors.

Recent findings: Recent studies confirm that lymphoma survivors face a wide spectrum of lymphoma and chemotherapy-related late effects, including fatigue, cognitive and neurological symptoms, mental distress, endocrine and sexual dysfunction, bone and oral health issues, increased risk of infections, and reduced work ability. Cardiovascular complications and second cancers remain the leading causes of late mortality. New data are drawing attention to long-term complications following cellular and immunotherapies. Some survivorship care plans and nurse-led interventions have shown promising results, however lymphoma-specific studies and long-term follow-up remain limited.

Summary: Care for lymphoma survivors is becoming an increasingly important part of long-term management. Long-term follow-up care remains highly heterogeneous across the world, lacking systematic and structured approaches. As treatment methods evolve, survivorship models must adapt accordingly to ensure that long-term outcomes and quality of life are adequately addressed in the heterogeneous population of lymphoma survivors.

Keywords: cardiovascular toxicity; late effects; lymphoma survivorship; second malignancies.